CENU treatment induced bystander effects which are effective on parental and non-parental tumors and have a phospholipid metabolism proton NMR spectroscopy signature

International Journal of Oncology

Volumn 29, Issue 3, 2006, Pages 637-642

  Merle, Patrick ^a   Morvan, Daniel ^b,c,d   Madelmont, Jean Claude ^b   Caillaud, Denis ^a,d   Demidem, Aicha ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b INSERM   (France)

^c Centre de Lutte Contre le Cancer Jean Perrin   (France)

^d UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Bystander effects; Chloroethylnitrosoureas; Phospholipid metabolism; Proton NMR spectroscopy; Secondary tumors

Indexed keywords

1-(2-CHLOROETHYL)-1-NITROSOUREA; CHLOROETHYLNITROSOUREA; DRUG DERIVATIVE; ETHYLNITROSOUREA; N (2 CHLOROETHYL) N NITROSOACETAMIDE; N-(2-CHLOROETHYL)-N-NITROSOACETAMIDE; NITROSO DERIVATIVE; PHOSPHOLIPID; PROTON;

ANIMAL; ARTICLE; BYSTANDER EFFECT; C57BL MOUSE; CELL DIFFERENTIATION; DRUG EFFECT; EXPERIMENTAL MELANOMA; LEWIS CARCINOMA; LUNG TUMOR; METABOLISM; MOUSE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

ANIMALS; BYSTANDER EFFECT; CARCINOMA, LEWIS LUNG; CELL DIFFERENTIATION; ETHYLNITROSOUREA; LUNG NEOPLASMS; MAGNETIC RESONANCE SPECTROSCOPY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NITROSO COMPOUNDS; PHOSPHOLIPIDS; PROTONS;

EID: 33749335040     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.3.637     Document Type: Article

References (21)

1. Ewig RA and Kohn KW: DNA damage and repair in mouse leukemia L1210 cells treated with nitrogen mustard, 1,3-bis(2-chloroethyl)-1-nitrosourea, and other nitrosoureas. Cancer Res 37: 2114-2122, 1977.
2. Brent TP, Lestrud SO, Smith DG and Remack JS: Formation of DNA interstrand cross-links by the novel chloroethylating agent 2- chloroethyl(methylsulfonyl)methanesulfonate: suppression by O6-alkylguanine-DNA alkyltransferase purified from human leukemic lymphoblasts. Cancer Res 47: 3384-3387, 1987.
3. Demidem A, Morvan D, Papon J, De Latour M and Madelmont JC: Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Cancer Res 61: 2294-2300, 2001. (Pubitemid 32692062)
4. Demidem A, Morvan D and Madelmont JC: Bystander effects are induced by CENU treatment and associated with altered protein secretory activity of treated tumor cells: A relay for chemotherapy? Int J Cancer (In press).
5. Lyng FM, Seymour CB and Mothersill C: Initiation of apoptosis in cells exposed to medium from the progeny of irradiated cells: a possible mechanism for bystander-induced genomic instability? Radiat Res 157: 365-370, 2002.
6. Ohba K, Omagari K, Nakamura T, et al: Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis, Gut 43: 575-577, 1998. (Pubitemid 28462047)
7. Madelmont JC: Cystemustine. Drugs Future 19: 27-30, 1994.
8. Dolan ME, Moschel RC and Pegg AE: Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 87: 5368-5372, 1990. (Pubitemid 20260181)
9. Morvan D, Demidem A, Papon J and Madelmont JC: Quantitative HRMAS proton correlation spectroscopy applied to cultured melanoma cells treated by chloroethyl-nitrosourea: demonstration of phospholipid metabolism alterations. Magn Reson Med 49: 241-248, 2003. (Pubitemid 36159860)
10. Kwiatkowski F, Girard M, Hacene K and Berlie J: Sem: a suitable statistical software adaptated for research in oncology. Bull Cancer 87: 715-721, 2000.
11. Morvan D, Demidem A, Papon J, De Latour M and Madelmont JC: Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Cancer Res 62: 1890-1897, 2002.
12. Adris S, Chuluyan E, Bravo A, et al: Mice vaccination with interleukin 12-transduced colon cancer cells potentiates rejection of syngeneic non-organ-related tumor cells. Cancer Res 60: 6696-6703, 2000.
13. Cui Z, Houweling M, Chen MH, Record M, Chap H, Vance DE and Tercé FA: Genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese Hamster Ovary cells. J Biol Chem 271: 14668-14671, 1996. (Pubitemid 26194939)
14. Mallampalli RK, Ryan AJ, Salom RG and Jackowski S: Tumor necrosis factor-alpha inhibits expression of CTP:phosphocholine cytidylyltransfé rase. J Biol Chem 275: 9699-9708, 2000. (Pubitemid 30185203)
15. Itoh K, Nakamura M and Akino T: Comparison of phospholipid profiles of primary adenocarcinoma in the lung and other organs. Lipids 12: 876-880, 1981. (Pubitemid 12189270)
16. Baburina I and Jackowski S: Cellular response to excess phospholipid. J Biol Chem 274: 9400-9408, 1999.
17. McPhail LD, Chung YL, Madhu B, Clark S, Griffiths JR, Kelland LR and Robinson S: Tumor dose response to the vascular disrupting agent 5,6-dimethylxanthenome-4-acetic acid, using in vivo magnetic resonance spectroscopy. Clin Cancer Res 11: 3705-3713, 2005.
18. De Jong S, Mulder NH, De Vries EGC and Robillard GT: NMR spectroscopy analysis of phosphorus metabolites and the effect of adriamycin on these metabolite levels in an adriamycin-sensitive and resistant human small cell lung carcinoma cell line. Br J Cancer 63: 205-212, 1991.
19. Griffin JL and Shockcor JP: Metabolic profiles of cancer cells. Nat Rev 4: 551-561, 2004.
20. Glunde K, Chunfa J and Bhujwalla ZM: Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64: 4270-4276, 2004.
21. Kiss Z: Regulation of mitogenesis by water-soluble phospholipid intermediates. Cell Signal 11: 509-514, 1999.